Yadong Yu

Yadong Yu has a diverse and extensive work experience. Starting in 2005, Yu worked as a Postdoctoral Scholar at the National Institutes of Health, where they investigated the interactions between NMDA receptors and calmodulin. They co-expressed and purified the two proteins from E. coli. From 2007 to 2013, Yu transitioned to a Postdoctoral Scholar position at UCSF, leading a study on proteasome degradation mechanisms and publishing results in prominent journals. They also carried out a project on determining nucleotide binding stoichiometry in proteasomal ATPase hexamer. At Berkeley Lab from 2013 to 2016, Yu worked as a Research Scientist studying human plasma lipoproteins and published the polyhedral 3D structure of VLDL. They were also responsible for troubleshooting and maintaining electron microscope equipment. From 2016 to 2019, Yu joined LakePharma, Inc. as a Senior Scientist, initially working in the Protein Chemistry group and later transitioning to the Antibody Engineering group. During this time, Yu played various roles, including purifying and characterizing proteins, establishing process development for non-tagged proteins, and leading a contract project for analyzing low-abundance proteins. Most recently, Yu worked at Immutics from 2019 to 2020 as a Senior Scientist II in Biophysics. In November 2020, Yu joined Nektar Therapeutics as a Senior Scientist.

Yadong Yu completed a Bachelor's degree in pharmaceutics from China Pharmaceutical University from 1993 to 1997. Subsequently, from 2000 to 2005, they pursued a Ph.D. in Biochemistry and Molecular Biology at the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences.